Allogene Therapeutics (ALLO) Competitors $1.19 +0.07 (+6.25%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.22 +0.03 (+2.52%) As of 08/22/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLO vs. CRMD, MLYS, NUVB, ORIC, IOVA, SION, TRVI, URGN, CRON, and IMNMShould you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include CorMedix (CRMD), Mineralys Therapeutics (MLYS), Nuvation Bio (NUVB), Oric Pharmaceuticals (ORIC), Iovance Biotherapeutics (IOVA), Sionna Therapeutics (SION), Trevi Therapeutics (TRVI), Urogen Pharma (URGN), Cronos Group (CRON), and Immunome (IMNM). These companies are all part of the "pharmaceutical products" industry. Allogene Therapeutics vs. Its Competitors CorMedix Mineralys Therapeutics Nuvation Bio Oric Pharmaceuticals Iovance Biotherapeutics Sionna Therapeutics Trevi Therapeutics Urogen Pharma Cronos Group Immunome CorMedix (NASDAQ:CRMD) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership. Which has more risk & volatility, CRMD or ALLO? CorMedix has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Is CRMD or ALLO more profitable? CorMedix has a net margin of 42.11% compared to Allogene Therapeutics' net margin of 0.00%. CorMedix's return on equity of 42.73% beat Allogene Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CorMedix42.11% 42.73% 34.19% Allogene Therapeutics N/A -55.99%-42.75% Which has stronger earnings & valuation, CRMD or ALLO? CorMedix has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorMedix$43.47M23.51-$17.93M$0.7518.25Allogene TherapeuticsN/AN/A-$257.59M-$1.11-1.07 Do analysts recommend CRMD or ALLO? CorMedix presently has a consensus price target of $16.71, indicating a potential upside of 22.09%. Allogene Therapeutics has a consensus price target of $8.44, indicating a potential upside of 609.62%. Given Allogene Therapeutics' higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Allogene Therapeutics 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.75 Do institutionals & insiders have more ownership in CRMD or ALLO? 34.2% of CorMedix shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 5.3% of CorMedix shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media prefer CRMD or ALLO? In the previous week, Allogene Therapeutics had 4 more articles in the media than CorMedix. MarketBeat recorded 4 mentions for Allogene Therapeutics and 0 mentions for CorMedix. CorMedix's average media sentiment score of 1.00 beat Allogene Therapeutics' score of -0.07 indicating that CorMedix is being referred to more favorably in the media. Company Overall Sentiment CorMedix Positive Allogene Therapeutics Neutral SummaryCorMedix beats Allogene Therapeutics on 11 of the 16 factors compared between the two stocks. Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLO vs. The Competition Export to ExcelMetricAllogene TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$248.51M$3.11B$5.75B$9.62BDividend YieldN/A2.23%4.40%4.10%P/E Ratio-1.0721.1431.2526.05Price / SalesN/A345.39433.91193.97Price / CashN/A43.1937.7358.48Price / Book0.778.129.536.61Net Income-$257.59M-$54.72M$3.26B$265.65M7 Day Performance8.18%2.62%2.13%2.03%1 Month Performance-28.31%2.68%2.80%-0.31%1 Year Performance-54.41%10.93%30.68%19.06% Allogene Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLOAllogene Therapeutics2.8357 of 5 stars$1.19+6.3%$8.44+609.6%-54.1%$248.51MN/A-1.07310CRMDCorMedix2.6479 of 5 stars$13.10+1.3%$16.71+27.6%+168.4%$965.21M$43.47M17.2430MLYSMineralys Therapeutics3.4114 of 5 stars$15.34+5.6%$32.25+110.2%+32.1%$962.61MN/A0.0028Analyst UpgradeNUVBNuvation Bio2.3248 of 5 stars$2.90+5.5%$7.33+152.9%+3.5%$941.25M$7.87M-4.6060Positive NewsORICOric Pharmaceuticals4.7708 of 5 stars$9.90+2.5%$17.63+78.0%+6.0%$938.21MN/A0.0080IOVAIovance Biotherapeutics4.8069 of 5 stars$2.50-2.0%$11.90+376.0%-76.9%$922.73M$164.07M-2.03500Analyst ForecastShort Interest ↓SIONSionna Therapeutics2.0598 of 5 stars$21.39+2.7%$38.50+80.0%N/A$918.99MN/A0.0035News CoverageHigh Trading VolumeTRVITrevi Therapeutics3.0828 of 5 stars$7.45-0.9%$20.38+173.5%+173.6%$915.76MN/A-17.7420Analyst ForecastURGNUrogen Pharma4.5459 of 5 stars$19.40-1.6%$31.43+62.0%+34.5%$911.87M$90.40M-5.84200CRONCronos Group0.7375 of 5 stars$2.53+6.8%N/A+12.6%$907.80M$117.61M50.60450Gap UpIMNMImmunome2.0093 of 5 stars$10.25-0.3%$23.14+125.8%-29.4%$894.82M$9.04M-3.3340News CoverageAnalyst ForecastGap Up Related Companies and Tools Related Companies CRMD Competitors MLYS Competitors NUVB Competitors ORIC Competitors IOVA Competitors SION Competitors TRVI Competitors URGN Competitors CRON Competitors IMNM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLO) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access